// App-Quantinova.ai

3209 : CRLX101, an investigational nanoparticle-drug conjugate of camptothecin, demonstrates synergy with immunotherapy agents in preclinical models

Researchers

Presenter

  • Douglas Lazarus

Principal Investigators

  • Christian Peters

  • Adam Stockmann

  • Scott Eliasof

  • Lata Jayaraman

Medical Centers

  • Cerulean Pharma Inc, Waltham, MA

Locations

  • United States

Companies

  • Cerulean Pharma Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Hypoxia-inducible factor-1

Drug/Treatment

  • camptothecin

  • CRLX101

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved